학술논문

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
Document Type
Article
Source
Investigational New Drugs; Aug2020, Vol. 38 Issue 4, p1096-1107, 12p
Subject
ANTINEOPLASTIC agents
BALDNESS
BREAST tumors
CLINICAL trials
DRUG tolerance
DRUG efficacy
DRUG toxicity
ENZYME inhibitors
NEUTROPENIA
OVARIAN tumors
PACLITAXEL
PATIENT safety
PHARMACEUTICAL arithmetic
PREANESTHETIC medication
THROMBOCYTOPENIA
ALANINE aminotransferase
TREATMENT effectiveness
RECEIVER operating characteristic curves
CARBOPLATIN
INVESTIGATIONAL drugs
CANCER fatigue
PHARMACODYNAMICS
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)